Skip to main content
. Author manuscript; available in PMC: 2011 Dec 15.
Published in final edited form as: Cancer Res. 2010 Dec 15;70(24):10150–10160. doi: 10.1158/0008-5472.CAN-10-1852

Figure 5.

Figure 5

Angiopoetin-1 and -2 trigger ERK phosphorylation. (A). HUVECs were treated with 200 ng/ml of angiopoietin-1 or 500 ng/ml angiopoietin-2 for varying times. Cell lysates were analyzed for phospho-ERK with immunoblotting. (B). HUVECs were treated for ten minutes with varying concentrations of angiopoietin-1 and -2, and then phospho-ERK was assayed with immunoblotting. (C). Phospho-ERK levels from (B) were analyzed with an ELISA.